WEBULL
WebtradeDownload

Supernus Pharmaceuticals (SUPN) Just Drew Fresh Attention, What Is The Market Weighing?

Simply Wall St · 1d ago

Conference appearances put Supernus Pharmaceuticals in focus

Supernus Pharmaceuticals (SUPN) is set to brief investors at two healthcare conferences on 9 and 10 September 2026, giving the biopharma group a fresh platform to outline its central nervous system portfolio.

Recent trading has been softer, with the share price down 11.69% over the past month and 15.83% year to date at US$41.64. However, a 3-year total shareholder return of 42.46% and 5-year total shareholder return of 52.64% point to a more resilient longer record for Supernus Pharmaceuticals.

Compare Supernus Pharmaceuticals with a curated group of CNS focused peers and other biopharma opportunities using our hand picked 16 high quality undiscovered gems.

Supernus Pharmaceuticals has built a sizeable US$830.4 million central nervous system franchise, yet the share price has slipped in recent months. Is that a temporary markdown or a fair reset on what the business is worth today?

Most Popular Narrative: 33.7% Undervalued

On the most followed narrative, Supernus Pharmaceuticals screens as undervalued, with a fair value of $62.83 against the recent $41.64 share price, putting the focus squarely on its long term earnings blueprint.

Life cycle management and product differentiation (e.g., Qelbree’s strong adoption in untreated and switch patients, ONAPGO's novel delivery and add-on use) create defensive moats, supporting sustained net margin expansion as established products mature.

Read the complete narrative.

Want to see how this story hangs together? The revenue curve, the margin lift and the future earnings multiple all link into one tight valuation script. Curious which assumptions really carry the weight in that $62.83 number? The full narrative lays it out in plain English.

Result: Fair Value of $62.83 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

Still, the Supernus Pharmaceuticals story can break if pricing pressure on key drugs and heavier R&D and SG&A spending keep operating results close to losses.

Find out about the key risks to this Supernus Pharmaceuticals narrative.

Another view on Supernus Pharmaceuticals valuation

On a simple sales multiple, Supernus Pharmaceuticals looks expensive versus its closest peers, with a P/S of 2.9x compared with 1.7x. Against the wider US Pharmaceuticals group though, that same 2.9x sits below the 5.3x average and the 6.1x fair ratio that the market could move toward. Is this a premium to worry about or a gap that might eventually close?

See what the numbers say about this price — find out in our valuation breakdown.

NasdaqGM:SUPN P/S Ratio as at Sep 2026
NasdaqGM:SUPN P/S Ratio as at Sep 2026

Next Steps

Mixed signals in the Supernus Pharmaceuticals story can be useful. Act while the conference spotlight is fresh and weigh the upside yourself with 3 key rewards.

Ready to find more opportunities beyond Supernus Pharmaceuticals?

If Supernus Pharmaceuticals has caught your attention, do not stop there. Fresh ideas often come from comparing it with other markets, sectors and business models.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.